Haemonetics (HAE) vs ICU Medical (ICUI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Haemonetics (HAE) has outperformed ICU Medical (ICUI) over the past year, gaining 134.3% versus a gain of 30.6%. Over five years, HAE leads with a +70.9% price change compared with -31.9% for ICUI. Haemonetics is the larger company by market cap ($5.44 billion vs $3.93 billion), about 1.4 times the size.
On valuation, ICU Medical trades at a lower forward P/E (16.3x vs 20.5x for Haemonetics). Haemonetics converts more of its revenue into profit, with a net margin of 7.3% versus 0.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | ICUI |
|---|---|---|
| Share price | $119.47 | $157.18 |
| Market cap | $5.44B | $3.93B |
| 1-day change | +17.46% | +0.74% |
| YTD return | +49.06% | +10.17% |
| 1-year return | +134.35% | +30.65% |
| 5-year return | +70.89% | -31.91% |
| P/E ratio (TTM) | 57.71 | 132.08 |
| Forward P/E | 20.53 | 16.29 |
| EPS (TTM) | $2.07 | $1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | $2.23B |
| Revenue growth (YoY) | -1.97% | -6.33% |
| Net income (latest FY) | $97.31M | $732.00K |
| Gross margin | 59.04% | 36.84% |
| Operating margin | 11.75% | 1.92% |
| Net margin | 7.29% | 0.03% |
| 52-week high | $121.00 | $192.85 |
| 52-week low | $48.17 | $112.50 |
| Distance from 52-week high | -1.26% | -18.50% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -6.67% | +23.03% |
| Average volume | 715.68K | 277.18K |
| Shares outstanding | 45.50M | 25.01M |
| Employees | 3,009 | 13,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HAE has outperformed ICUI by 103.7 percentage points over the past year.
- ICU Medical trades at a higher earnings multiple (132.1x vs 57.7x trailing P/E).
- Haemonetics is more profitable, keeping 7.3 cents of every revenue dollar as net income versus 0.0 cents for ICU Medical.
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About ICU Medical
ICUI stock →ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products.
Health Care · Medical/Dental Instruments · 13,000 employees
HAE vs ICUI FAQ
Which is bigger, Haemonetics or ICU Medical?
Haemonetics (HAE) is larger, with a market capitalization of $5.44B compared with $3.93B for ICU Medical (ICUI).
Which stock has performed better over the past year, HAE or ICUI?
HAE returned +134.35% over the past 12 months, compared with +30.65% for ICUI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HAE or ICUI?
HAE has the lower trailing P/E at 57.7, versus 132.1 for ICUI. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Haemonetics and ICU Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.